Profile data is unavailable for this security.
About the company
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
- Revenue in EUR (TTM)1.15bn
- Net income in EUR159.85m
- Incorporated--
- Employees3.23k
- LocationDiaSorin SpAvia Crescentino sncSALUGGIA 13040ItalyITA
- Phone+39 161487526
- Fax+39 161487670
- Websitehttps://www.diasorin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Camurus AB | 159.68m | 39.46m | 2.93bn | 218.00 | 74.58 | 12.65 | 72.02 | 18.37 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| Virbac SA | 1.25bn | 121.30m | 3.03bn | 5.46k | 24.93 | 3.33 | 18.01 | 2.43 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
| Dottikon ES Holding AG | 333.56m | 82.43m | 3.75bn | 726.00 | 44.90 | 4.07 | 36.22 | 11.24 | 5.84 | 5.84 | 23.62 | 64.31 | 0.2905 | 0.6518 | 5.23 | 449,407.70 | 7.18 | 7.83 | 8.39 | 8.95 | 66.55 | 75.24 | 24.71 | 24.25 | 1.57 | -- | 0.1014 | -- | 2.13 | 17.17 | -8.08 | 37.75 | 26.82 | -- |
| ALK-Abello A/S | 662.80m | 74.45m | 4.15bn | 2.83k | 61.23 | 7.20 | 36.28 | 6.26 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Siegfried Holding AG | 1.30bn | 114.56m | 4.15bn | 3.93k | 34.21 | 4.55 | 20.91 | 3.19 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Krka d.d. Novo Mesto | 1.83bn | 323.81m | 4.26bn | 11.80k | 12.40 | 1.78 | 10.00 | 2.32 | 10.48 | 10.48 | 59.36 | 73.17 | 0.6528 | 1.37 | 3.57 | 157,225.70 | 11.51 | 12.64 | 13.68 | 15.12 | 55.99 | 57.29 | 17.64 | 18.71 | 2.88 | 66.70 | 0.0056 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 2.05bn | 482.65m | 4.36bn | 11.60k | 8.92 | 1.40 | 7.07 | 2.12 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.67 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.38 |
| Laboratorios Farmaceuticos ROVI SA | 829.51m | 170.34m | 4.74bn | 2.11k | 27.38 | 8.43 | 24.77 | 5.71 | 3.20 | 3.20 | 15.58 | 10.41 | 0.9883 | 1.04 | 5.13 | 392,946.00 | 20.29 | 18.90 | 28.88 | 25.58 | 59.35 | 59.82 | 20.53 | 20.13 | 0.8575 | -- | 0.1075 | 33.60 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Hikma Pharmaceuticals Plc | 2.65bn | 175.27m | 5.03bn | 8.97k | 28.74 | 2.47 | 14.23 | 1.90 | 0.6712 | 0.6712 | 10.15 | 7.80 | 0.6284 | 1.76 | 3.67 | 251,683.50 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Orion Oyj | 1.22bn | 216.80m | 5.31bn | 3.70k | 24.22 | 7.44 | 20.11 | 4.35 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Zealand Pharma A/S | 46.18m | -99.10m | 5.37bn | 270.00 | -- | 14.04 | -- | 116.38 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| DiaSorin SpA | 1.15bn | 159.85m | 5.54bn | 3.23k | 34.51 | 3.43 | 18.74 | 4.82 | 2.87 | 2.87 | 21.49 | 28.83 | 0.3469 | 1.31 | 5.49 | 355,153.10 | 4.79 | 10.30 | 5.32 | 11.50 | 64.55 | 66.70 | 13.80 | 21.25 | 2.08 | 11.35 | 0.4368 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Grifols SA | 6.59bn | 59.31m | 5.71bn | 23.74k | 103.49 | 1.09 | 9.16 | 0.8655 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
| BACHEM HOLDING AG | 590.21m | 114.36m | 6.20bn | 2.01k | 53.93 | 4.59 | 38.61 | 10.50 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Croda International Plc | 1.99bn | 200.95m | 7.45bn | 5.85k | 37.12 | 2.69 | 21.25 | 3.74 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
Data as of May 31 2024. Currency figures normalised to DiaSorin SpA's reporting currency: Euro EUR
12.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.05m | 1.88% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 977.95k | 1.75% |
| Wellington Management Co. LLPas of 30 May 2024 | 906.46k | 1.62% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 838.98k | 1.50% |
| Invesco Advisers, Inc.as of 30 Apr 2024 | 832.53k | 1.49% |
| The Vanguard Group, Inc.as of 09 May 2024 | 800.01k | 1.43% |
| Shareholder Value Management AGas of 31 Oct 2023 | 478.80k | 0.86% |
| BlackRock Fund Advisorsas of 09 May 2024 | 435.90k | 0.78% |
| Impax Asset Management Ltd.as of 30 Apr 2024 | 324.60k | 0.58% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 314.32k | 0.56% |
More ▼
Data from 31 Oct 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
